Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression
Journal of Clinical Investigation · 01.06.2026 · 136 (11)
DOI: 10.1172/jci191508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.06.2026. Verfasst von Sebastian Michels und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Cell-Free Nucleic Acids, Epigenesis, Genetic, DNA Methylation. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
The role of the epigenome in age-related neurodegenerative disorders remains understudied. Here, we analyzed circulating cell-free DNA (cfDNA) from blood to detect methylation changes as a liquid biopsy for Amyotrophic Lateral Sclerosis (ALS). Our study included 20 patients with sporadic ALS, 10 patients with C9orf72-associated ALS, 10 asymptomatic carriers of the C9orf72 repeat expansion mutation, and 21 nondisease control individuals. Following targeted enzymatic methyl-sequencing (EM-seq) of approximately 4 million CpG sites, we detected numerous differentially methylated genes, including several implicated in ALS disease risk and pathogenesis. By integrating multiple epigenetic features, we delineated a distinct epigenetic signature, which achieved an average area under the curve (AUC) of 0.91 ± 0.10 upon receiver operator characteristic (ROC) analysis, which enabled detection of approximately 70% of patients with ALS with close to 100% specificity. Furthermore, we also identified a set of genes whose methylation status significantly correlated with clinical disease progression and cerebrospinal fluid (CSF) neurofilament levels. Our results reveal the potential of cfDNA-based biomarkers to accurately diagnose ALS and potentially predict disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Ulm, Ulm, Germany.
- Department of Biological Chemistry.
- Department of Pathology & Laboratory Medicine.
- Department of Psychiatry & Human Behavior, and.
- Department of Neurobiology & Behavior, University of California, Irvine, Irvine, California, USA.
- UCI Institute for Memory Impairment & Neurological Disorders, Irvine, California, USA.
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Michels, S., Chen, C., Ruf, W. P., Garcia Garcia, M. M., Arnold, F. J., Wu, Z., Bennett, C. L., Shams, D., Thompson, L. M., Walker, A. C., Dickson, D. W., Petrucelli, L., Dorst, J., Prudencio, M., Li, W., & La Spada, A. R. (2026). Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression. Journal of Clinical Investigation, 136(11). https://doi.org/10.1172/jci191508
Vancouver
Michels S, Chen C, Ruf WP, Garcia Garcia MM, Arnold FJ, Wu Z, et al. Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression. Journal of Clinical Investigation. 2026;136(11). doi:10.1172/jci191508
BibTeX
@article{Michels2026,
author = {Michels, Sebastian and Chen, Chaorong and Ruf, Wolfgang P and Garcia Garcia, M Madhy and Arnold, Frederick J and Wu, Zhuoxing and Bennett, Craig L and Shams, Daniel and Thompson, Leslie M and Walker, Alyssa C and Dickson, Dennis W and Petrucelli, Leonard and Dorst, Johannes and Prudencio, Mercedes and Li, Wei and La Spada, Albert R},
title = {Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {11},
doi = {10.1172/jci191508}
}
EUVIMED